These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 37434642)

  • 1. Kinase inhibitors in thyroid cancers.
    Sukrithan V; Jain P; Shah MH; Konda B
    Endocr Oncol; 2023 Jan; 3(1):e220062. PubMed ID: 37434642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.
    Cortas C; Charalambous H
    Life (Basel); 2023 Dec; 14(1):. PubMed ID: 38255638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RET kinase inhibitors for
    Vodopivec DM; Hu MI
    Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
    Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
    Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.
    Al-Jundi M; Thakur S; Gubbi S; Klubo-Gwiezdzinska J
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.
    Yun KM; Cohen EEW
    JCO Oncol Pract; 2024 Jul; 20(7):899-906. PubMed ID: 38452309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.
    Lorusso L; Cappagli V; Valerio L; Giani C; Viola D; Puleo L; Gambale C; Minaldi E; Campopiano MC; Matrone A; Bottici V; Agate L; Molinaro E; Elisei R
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current perspectives on the management of patients with advanced
    Elisei R; Grande E; Kreissl MC; Leboulleux S; Puri T; Fasnacht N; Capdevila J
    Front Oncol; 2023; 13():1141314. PubMed ID: 37207147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular features of aggressive thyroid cancer.
    Elia G; Patrizio A; Ragusa F; Paparo SR; Mazzi V; Balestri E; Botrini C; Rugani L; Benvenga S; Materazzi G; Spinelli C; Antonelli A; Fallahi P; Ferrari SM
    Front Oncol; 2022; 12():1099280. PubMed ID: 36605433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 11. Thyroid Cancer: A Review.
    Boucai L; Zafereo M; Cabanillas ME
    JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.
    Fullmer T; Cabanillas ME; Zafereo M
    Front Endocrinol (Lausanne); 2021; 12():720723. PubMed ID: 34335481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
    Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
    Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive molecular pathology in metastatic thyroid cancer: the role of
    Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Cabozantinib in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Carcinoma: Patient Selection and Reported Outcomes.
    Roof L; Geiger JL
    Cancer Manag Res; 2023; 15():343-350. PubMed ID: 37070083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.
    Porter A; Wong DJ
    Front Oncol; 2020; 10():592202. PubMed ID: 33569345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.